Physician profile
Daniel C Sufficool
NPI 1083098669
$2,278.31
in general payments reported to CMS, 2019-2025
33 companies · $17.85 in 2025
The $17.85 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $294 · 2023: $1,357 · 2024: $610 · 2025: $17.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.83 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $197.54 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $197.45 | 2022-2024 | |
| Siemens Medical Solutions USA, INC. | $171.22 | 2023 | |
| Octapharma USA, INC. | $151.68 | 2022-2024 | Octagam Immune Globulin (Human), Panzyga |
| Incyte Corporation | $144.38 | 2022-2024 | Jakafi, Monjuvi |
| Dendreon Pharmaceuticals LLC | $143.33 | 2022-2023 | Provenge |
| Sumitomo Pharma America, INC. | $131.01 | 2023 | Orgovyx |
| Sobi, INC | $97.58 | 2022-2024 | |
| Genzyme Corporation | $87.64 | 2022-2023 | |
| Progenics Pharmaceuticals, INC. | $69.67 | 2023 | Pylarify |
| Novocure INC. | $65.70 | 2023-2024 | Optune |
| Genentech USA, INC. | $62.39 | 2024-2025 | Lunsumio, Columvi, Polivy |
| Janssen Biotech, INC. | $60.32 | 2023-2024 | Rybrevant, Imbruvica |
| Eisai INC. | $54.62 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $47.58 | 2023 | Ultomiris |
| Myovant Sciences INC. | $43.38 | 2022 | |
| Mirati Therapeutics, INC. | $33.82 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $26.62 | 2024 | Qinlock |
| Karyopharm Therapeutics INC. | $24.64 | 2024 | Xpovio |
| Seagen INC. | $24.26 | 2022 | |
| Tersera Therapeutics LLC | $23.51 | 2023 | Quzyttir |
| Accord Healthcare, INC. | $21.01 | 2023 | |
| Agios Pharmaceuticals, INC. | $19.14 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.05 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.04 | 2023 | Empaveli |
| Adc Therapeutics America, INC. | $17.91 | 2024 | |
| Pharmaessentia USA Corporation | $17.74 | 2023 | Besremi |
| Amneal Pharmaceuticals LLC | $17.19 | 2024 | Avastin |
| Aveo Pharmaceuticals, INC. | $16.26 | 2023 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $15.44 | 2024 | Tagrisso |
| Tactile Systems Technology INC | $13.20 | 2023 | Entre Plus, Flexitouch Plus |
| Forte Bio-Pharma LLC | $9.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sufficool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.